DURECT Corporation
2 Results Way
Cupertino
California
95014
United States
Tel: 408-777-1417
Fax: 408-777-3577
Website: http://www.durect.com/
363 articles with DURECT Corporation
-
DURECT Corporation Reports First Quarter 2022 Financial Results and Update of Programs
5/4/2022
DURECT Corporation announced financial results for the three months ended March 31, 2022 and provided a corporate update.
-
DURECT Corporation to Announce First Quarter 2022 Financial Results and Provide Business Update on May 4
4/27/2022
DURECT Corporation announced that it will report its first quarter 2022 financial results and host a conference call after the market close on Wednesday, May 4, 2022.
-
DURECT Corporation To Present at the 2022 Cantor Fitzgerald Virtual Rare Orphan Disease Summit
3/23/2022
DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown , President and CEO, will be participating in a panel discussion at the Cantor Virtual Rare Orphan Disease Summit
-
DURECT Corporation Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference
3/9/2022
DURECT Corporation announced that Dr. James E. Brown, President and CEO, Dr. WeiQi Lin, Executive Vice President of R&D and Dr. Norman Sussman, Chief Medical Officer, will be participating in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc. at the Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022.
-
DURECT Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Update of Programs
3/7/2022
DURECT Corporation announced financial results for the three months and year ended December 31, 2021 and provided a corporate update.
-
The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.
-
DURECT Corporation Doses First European Patient in Phase 2b AHFIRM Study of Larsucosterol(DUR-928) in Severe Alcohol-Associated Hepatitis
3/1/2022
DURECT Corporation (Nasdaq: DRRX) today announced it dosed the first patient in the European Union as part of its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the safety and efficacy of larsucosterol in severe alcohol-associated hepatitis (AH) patients.
-
DURECT Corporation to Announce Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on March 7
2/28/2022
DURECT Corporation announced that it will report its fourth quarter and full year 2021 financial results and host a conference call after the market close on Monday, March 7, 2022.
-
Biopharma Executive Perspectives on 2022
1/10/2022
BioSpace sat down with 12 executives who shared their thoughts on the coming year and decade. -
DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference
1/6/2022
DURECT Corporation announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, and Dr. Norman Sussman, Chief Medical Officer will present at the H.C. Wainwright Bioconnect Conference which will be available on demand starting on January 10, 2022.
-
Mark Charest, Ph.D., of LifeSci Fund Management, said the J.P. Morgan Healthcare Conference will set the tone for biotech stock performance in 1H 2022.
-
DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)
12/22/2021
- DURECT to receive near-term upfront cash payments totaling $6 million, potential additional milestone payments of up to $130 million and tiered low to mid double-digit royalties based on U.S. sales and Innocoll granted exclusive development and commercialization rights to POSIMIR in the United States.
-
BioSpace Movers & Shakers, Dec. 17
12/17/2021
As 2021 moves closer to its end, biopharma and life sciences companies from across the globe continue to strengthen their leadership teams and boards with these Movers & Shakers. -
DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Garcia
12/14/2021
DURECT Corporation announced the expansion of its board of directors with the appointment of Peter García, a biopharmaceutical industry veteran with over 25 years of financial leadership experience.
-
DURECT Corporation to Participate in Alcoholic Liver Disease Workshop Today at the 5th Annual NASH Summit
11/29/2021
DURECT Corporation announced it will participate in a workshop at the 5th Annual NASH Summit being held virtually.
-
Data Presentation Today at The Liver Meeting® 2021 Shows Increasing Hospital Admissions for Alcohol-Associated Hepatitis (AH) in the U.S.
11/12/2021
DURECT Corporation announced the presentation of data at the American Association for The Study of Liver Diseases The Liver Meeting® 2021 showcasing an increase of hospitalizations for alcohol-associated hepatitis in the U.S. of approximately 19% or approximately 4.8% per year between 2015 and 2018.
-
DURECT Corporation Reports Third Quarter 2021 Financial Results and Update of Programs
11/2/2021
DURECT Corporation announced financial results for the three months ended September 30, 2021 and provided a corporate update.
-
DURECT Corporation to Announce Third Quarter 2021 Financial Results and Provide Business Update on November 2
10/26/2021
DURECT Corporation (Nasdaq: DRRX) today announced that it will report its third quarter 2021 financial results and host a conference call after the market close on Tuesday, November 2, 2021 .
-
DURECT Corporation Fireside Chat at the Cantor Fitzgerald Global Healthcare Conference 2021
9/23/2021
DURECT Corporation announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Kristen Kluska, Director, Equity Research Analyst at Cantor Fitzgerald.
-
DURECT Corporation Fireside Chat at Oppenheimer's Fall Healthcare Life Sciences & MedTech Summit
9/15/2021
DURECT Corporation announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc.